Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

510(k) for Radionics' NeuroMap system:

This article was originally published in Clinica

Executive Summary

The FDA has cleared Radionics' NeuroMap system for functional neurosurgery. It is designed to treat patients with movement disorders, in particular Parkinson's disease, by allowing doctors to precisely locate brain structures such as the pallidum and thalamus. The system analyses electrical signals in the brain to target these structures before treatment is performed. NeuroMap forms part of the NeuroPlan package developed by the Burlington, Massachusetts-based company.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel